TruthArchive.ai - Related Video Feed

The speaker discusses the use of mRNA in food and mentions a presentation about genetically engineering mosquitoes to deliver vaccines through mosquito bites. They mention that the Gates Foundation is funding this research, although they don't have proof of its viability. The speaker clarifies that they are not suggesting that the mosquitoes are currently injecting anyone with anything, but they have evidence that efforts are being made to enable mosquito injections.

In Chicago, Medicago uses plants as bioreactors to grow vaccines. They insert virus gene sequences into Agrobacterium tumphatians bacteria, which is then absorbed by the plants. After a few days in a greenhouse, the plants start producing virus-like particles, the key component of the vaccines.

CRISPR, a lab technique, can alter mosquito DNA to decrease their population or prevent them from carrying parasites. Discussions are underway with African countries to determine the necessary tests and trials before implementing this technique. Although it will take several years to obtain country approvals, the potential to reduce mosquito populations and eliminate malaria locally is promising. The speaker even brought some mosquitoes to the auditorium to provide firsthand experience. They emphasize that it is unfair for only poor people to face this issue.

In Medellin, Colombia, the world's largest mosquito factory is producing 30 million mosquitoes per week for the World Mosquito Program. By introducing Wolbachia bacteria into the mosquitoes, their ability to transmit diseases like dengue is stopped. The process involves releasing Wolbachia-infected mosquitoes into the wild population through mating. The factory houses mosquito eggs, larvae, and pupae, which are sorted by sex to manipulate the sex ratio. The mosquitoes are fed blood and then either packaged as eggs or released as adults into the field. With over half the world's population at risk of these diseases, the goal is to scale and deliver this solution to communities in need.

A malaria control squad enters an abandoned village to disperse DDT, a powerful insecticide. DDT is applied as an oil solution using power spraying equipment, effectively eliminating disease-carrying insects. Residual treatment of surfaces like walls, mattresses, and bed frames ensures long-lasting protection. Other areas such as galleys, mess halls, screens, garbage racks, and fly habitats are also treated. DDT is used to prevent the spread of disease vectors on planes and in military operations. Larva siding is crucial for mosquito control, and DDT solutions are effective in destroying larvae. Dispersal of DDT from planes provides even coverage in inaccessible areas. Ongoing research aims to improve DDT formulas and application methods.

Chicago's manufacturing facility is using a unique technology called virus like particles to grow vaccines. Medicago, the company behind this process, uses plants as mini bioreactors. They start by synthesizing the virus code into a biological product using the gene sequence. The code is inserted into bacteria called Agrobacterium tungfaciens, which is then submerged with the plants in a bacterial bath. The plants absorb the information and continue growing in a controlled greenhouse for at least 4 days. During this time, they start producing virus like particles, which are the crucial ingredient for the vaccines.

In Chicago's manufacturing facility, a new type of vaccine is being developed using a technology called virus like particles. Medicago, the company behind it, uses plants as mini bioreactors. They start by synthesizing the gene sequence of a virus into a biological product. The plants absorb this information through a bath with bacteria, which is then replaced with liquid using a vacuum. After spending at least 4 days in a controlled greenhouse, the plants begin producing virus like particles, the key ingredient for the vaccines.

Hi. I'm Scott O'Neill here in Medellin, Colombia today, and I'm at the world's biggest mosquito factory for the World Mosquito Program. We're making in here 30,000,000 mosquitoes a week. We've been able to bring the solution of Wolbachia mosquitoes to the city. When this bacteria called Wolbachia gets introduced into the mosquito, it stops their ability to transmit dengue. We release mosquitoes that have Wolbachia, and then they go and mate, and Wolbachia gets passed into the wild mosquito population. If we're going to control these diseases in all the tropical cities of the world, it's gonna require a lot of mosquitoes. The mosquito life cycle starts with the egg, and in this room, we've got a lot of eggs. Each one of these strips, these tiny black dots are up to 10,000 mosquito eggs.

We are discussing regulation and the use of CRISPR to reduce mosquito populations and combat malaria. We are working with African countries on necessary trials. It will take time to get approvals, but the potential to eliminate disease locally is promising. Malaria is transmitted by mosquitoes, and we are demonstrating this by releasing some in the auditorium. Everyone should understand the impact, not just the poor.

In Medellin, Colombia, the world's largest mosquito factory is producing 30 million mosquitoes per week for the World Mosquito Program. They are using Wolbachia bacteria to stop the transmission of diseases like dengue, Zika, and chikungunya. The factory starts with mosquito eggs, which hatch into larvae and then pupae. The males and females are sorted, with more females being desired. The adult mosquitoes are either packaged as eggs in gelatin capsules or released directly into the field. The goal is to scale this solution and deliver it to communities worldwide that are affected by these diseases.

The speaker states that mRNA in food is a critical issue, but also highlights the potential for transgenic mosquitoes to deliver vaccines via saliva. They reference a presentation about producing a transgenic mosquito as a "flying syringe" to deliver protective vaccines. The speaker claims the Gates Foundation is funding genetic engineering of mosquitoes with the intention of using mosquito bites for vaccination. While they don't have definitive proof of its viability, they assert that this research is underway. The speaker clarifies they are not claiming current mosquitoes are injecting people with anything. However, they state they have indisputable evidence that efforts are being made to enable mosquitoes to inject people with substances in the future.

There is a technique called CRISPR in the lab that can manipulate mosquito DNA to reduce their population or eliminate the disease they carry. Discussions are ongoing with African countries to determine the necessary tests and trials before implementing this solution. However, obtaining country approvals will take several years. Despite the time frame, the potential of reducing mosquito population and eradicating the disease locally makes this approach highly promising.

Chicago's manufacturing facility is using a unique method called virus like particle technology to grow vaccines. Medicago, the company behind this process, starts by synthesizing the gene sequence of a virus into a biological product. They insert this code into bacteria, which then carries it into plant cells. The plants absorb the code and begin producing virus like particles, the key ingredient of the vaccines. After a four-day growth period in a controlled greenhouse, the plants are ready for vaccine production.

In Medellin, Colombia, the world's largest mosquito factory is producing 30 million mosquitoes per week for the World Mosquito Program. They are using Wolbachia bacteria to prevent the transmission of diseases like dengue, Zika, and chikungunya. The process involves introducing Wolbachia into the mosquitoes, which then pass it on to the wild mosquito population through mating. The factory houses mosquito eggs, larvae, and pupae, which are sorted by sex to manipulate the sex ratio in the cages. The mosquitoes are fed blood and can be released into the field either as eggs or as adults. The program aims to scale and deliver this solution to communities worldwide.

I'm Scott O'Neill in Medellin, Colombia at the world's largest mosquito factory for the World Mosquito Program. We produce 30 million Wolbachia mosquitoes weekly to combat diseases like dengue. The Wolbachia bacteria stops mosquitoes from transmitting dengue. We breed mosquitoes from eggs to adults, sorting males and females to control the sex ratio. The females are released into the field after feeding on blood. Our goal is to reduce mosquito-borne diseases in tropical cities worldwide.

A billion genetically modified mosquitoes are being released in the Florida Keys to combat diseases like dengue, yellow fever, and Zika. This is the first time such mosquitoes are being released in the US. The British biotech company, Oxitec, obtained permission from the EPA to release them across 6,000 acres in Florida and Texas. However, a 2019 Yale University study warned that this plan could have unintended consequences. It suggested that the release of these mosquitoes could lead to the creation of hybrid mosquito babies that are more resistant to insecticides, potentially worsening the spread of diseases. The potential risks raise concerns about the success of this initiative.

Chicago's manufacturing facility is using a technology called virus like particles to grow a new type of vaccine. Medicago, the company behind this process, uses plants as mini bioreactors. They start by obtaining the gene sequence of a virus and insert it into bacteria called Egerobacterium tumfaciens. The plants are then submerged in a bath with the bacteria, allowing the genetic information to be absorbed by the plant cells. The air between the plant cells is replaced with liquid using a vacuum. After the plants' bacterial bath, they are returned to a controlled greenhouse.

Malaria's impact is greatly underestimated, with over 200 million people suffering from it at any given time. This hinders economic progress in affected areas. Malaria is transmitted by mosquitoes, which I have brought here for you to experience. We will release them in the auditorium so everyone can understand. These mosquitoes are not infected.

In Medellin, Colombia, the world's largest mosquito factory is producing 30 million mosquitoes per week for the World Mosquito Program. The goal is to combat diseases like dengue, Zika, and chikungunya by introducing a bacteria called Wolbachia into the mosquitoes, which stops their ability to transmit dengue. The factory houses millions of mosquito eggs, which hatch into larvae and eventually become adult mosquitoes. The males and females are sorted to manipulate the sex ratio in the cages. The mosquitoes are fed blood and then released into the field once they are fully grown.

Malaria eradication is challenging, but gene drive technology could change the genetics of mosquitoes to help achieve this goal. Mosquitoes can be genetically modified to act as "flying syringes" that deliver malaria vaccines when they bite humans. However, there are concerns about the potential risks of spreading malaria and the ethical implications of genetically modifying mosquitoes without informed consent. Despite these concerns, the development of new tools and technologies is crucial for malaria eradication.

In Medellin, Colombia, the world's largest mosquito factory is producing 30 million mosquitoes per week. This is done to combat diseases like dengue, Zika, and chikungunya. By introducing a bacteria called Wolbachia into the mosquitoes, their ability to transmit dengue is stopped. The factory houses millions of mosquito eggs, which hatch into larvae and eventually become adults. The males and females are sorted, with more females being desired. The adult mosquitoes are then released into the field. The mosquitoes are fed blood to sustain them. This massive production of mosquitoes is necessary to control diseases in tropical cities worldwide.

In 1956, the US military released Aedes aegypti mosquitoes infected with the malaria virus in Savannah, Georgia as part of Operation Big Buzz. Now, the military is testing genetically modified mosquitoes to deliver vaccinations, funded by the Bill and Melinda Gates Foundation. However, some residents are concerned about the potential risks and lack of scientific investigation. Similar efforts are being made in Houston to combat the Zika virus. Meanwhile, Oxford University has developed a vaccine that could reduce malaria deaths by 70% by 2030. In Fresno, California, a project is releasing a million mosquitoes per week to reduce the population. In Medellin, Colombia, Wolbachia-infected mosquitoes are being released to control diseases like dengue.

In this video, the speaker discusses the challenges of eradicating malaria and the potential use of genetically modified mosquitoes to deliver vaccines. They express concerns about the spread of malaria if the genetic modification fails and question the ethical implications of releasing modified mosquitoes without informed consent. Another speaker highlights the importance of considering climate change and its impact on the geographic range of disease-carrying mosquitoes. They emphasize the need to prevent, prepare for, and respond to emerging pathogens, using the systems and tools developed for COVID-19 as examples. The speaker also mentions the efforts made by countries to strengthen their healthcare systems for various diseases.

We conducted a study in Senegal to see how Ivermectin, given to people for river blindness, affected mosquitoes that transmit malaria. By catching mosquitoes before and after treatment, we found that the drug killed most adult mosquitoes, particularly the ones that transmit malaria. Although the total number of mosquitoes didn't decrease significantly, the drug effectively eliminated the old females responsible for spreading malaria.

Researchers at the Bill Gates Foundation-backed Leiden University Medical Center are developing genetically modified mosquitoes to deliver malaria vaccines. A recent study showed that 8 out of 9 participants who received bites from one type of modified mosquito were protected against malaria, while those in the placebo group received no protection. Despite safety concerns and ethical issues regarding informed consent, the research continues, with plans for larger trials and potential applications for other diseases. Meanwhile, an Australian regulatory body is reviewing an application to release genetically modified mosquitoes to combat dengue fever. The implications of using insects as vaccine carriers raise significant ethical questions, and there are ongoing calls for accountability regarding these experiments.